|
Dec. 15, 2020 |
|
|
June. 21, 2024 |
|
|
jRCT2051200096 |
ONO-4578-03:Phase 1 study of ONO-4578 given as monotherapy and combinations of ONO-4578 and ONO-4538 as sequential treatment (neoadjuvant therapy) after chemoradiation therapy in subjects with resectable advanced rectal cancer |
|
ONO-4578-03:ONO-4578 Phase 1 Study |
Hirashima Yoshinori |
||
Ono Pharmaceutical Co.,LTD |
||
3 -1 -1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan |
||
+81-120-626-190 |
||
clinical_trial@ono-pharma.com |
||
Center Information Medical |
||
Ono Pharmaceutical Co.,LTD |
||
3 -1 -1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan |
||
+81-120-626-190 |
||
clinical_trial@ono-pharma.com |
Complete |
Dec. 15, 2020 |
||
| Jan. 20, 2021 | ||
| 30 | ||
Interventional |
||
non-randomized controlled trial |
||
open(masking not used) |
||
uncontrolled control |
||
single assignment |
||
treatment purpose |
||
1. Rectal adenocarcinoma |
||
1. Patients with severe complication |
||
| 20age old over | ||
| 80age old not | ||
Both |
||
Resectable rectal cancer |
||
ONO-4578 and combinations of ONO-4578 and ONO-4538 as neoadjuvant therapy |
||
Safety, tolerability |
||
| Ono Pharmaceutical Co.,LTD |
| National Hospital Organization Osaka National Hospital Institutional Review Board I | |
| 2-1-14, Hoenzaka, Chuo-ku, Osaka city, Osaka | |
+81-6-6942-1331 |
|
| Approval | |
Nov. 24, 2020 |
No |
none |